AstraZeneca’s (AZN) “Buy” Rating Reaffirmed at Berenberg Bank

Berenberg Bank restated their buy rating on shares of AstraZeneca (LON:AZN) in a report released on Wednesday,London Stock Exchange reports. The firm currently has a GBX 140 ($1.80) price objective on the biopharmaceutical company’s stock.

AZN has been the topic of several other reports. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a report on Friday, March 7th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a research note on Wednesday, February 19th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, AstraZeneca presently has an average rating of “Moderate Buy” and a consensus target price of GBX 7,542.80 ($97.11).

AstraZeneca Stock Down 0.1 %

Shares of LON:AZN traded down GBX 8 ($0.10) during midday trading on Wednesday, reaching £112.24 ($144.51). The company’s stock had a trading volume of 16,843,158 shares, compared to its average volume of 23,815,352. The company has a quick ratio of 0.59, a current ratio of 0.93 and a debt-to-equity ratio of 73.83. The firm has a 50 day moving average of £115.70 and a 200-day moving average of £112.80. The firm has a market capitalization of £215.95 billion, a P/E ratio of 30.77, a PEG ratio of 0.86 and a beta of 0.17. AstraZeneca has a 12-month low of GBX 9,670 ($124.50) and a 12-month high of £133.88 ($172.37).

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.